

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-6 (Canceled).

Claim 7 (Previously Presented): A pharmaceutical composition containing the imidazole compound of claim 16, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable organic or inorganic excipient.

Claim 8 (Currently Amended): A pharmaceutical preparation containing the imidazole compound of claim 16, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable organic or inorganic excipient, which is used as an agent for the ~~prophylaxis or~~ treatment of impaired glucose tolerance disorder, diabetes, gestational diabetes, diabetic complications, insulin resistance syndrome, polycystic ovary syndrome, hyperlipidemia, atherosclerosis, hyperglycemia, osteoporosis, hyperuricemia, hypertension, or skin disorders related to an anomaly of differentiation of epidermic cells.


Claim 9 (Canceled).

Claim 10 (Currently Amended): A method of ~~preventing or~~ treating a disease in a patient treatable with a pharmaceutical compound having hypoglycemic activity selected from the group consisting of impaired glucose tolerance disorder, diabetes, gestational diabetes, diabetic complications, insulin resistance syndrome, polycystic ovary syndrome, hyperlipidemia, atherosclerosis, hyperglycemia, osteoporosis, hyperuricemia, hypertension, and skin disorders related to an anomaly of differentiation of epidermic cells, which

comprises administering to the patient the hypoglycemically active imidazole compound of claim 16 or a pharmaceutically acceptable salt thereof.

Claims 11-14 (Canceled).

Claim 15 (Previously Presented): An imidazole compound of the formula:



wherein

R² is a lower alkyl;

R³ is chlorine;

R⁴ is (1) a lower alkenyl optionally substituted by aryl or heterocyclic group, (2) aryl optionally substituted by lower alkenyl, (3) lower alkyl, or (4) heterocyclic group optionally substituted by halogen;

R⁶ is lower alkenyl optionally substituted by phenyl, or lower alkynyl optionally substituted by phenyl; and

L is ethylene,

where aryl is defined as unsubstituted aryl or alkyl-substituted aryl, or a salt thereof.

Claim 16 (Currently Amended): The imidazole compound of claim 15 which is:

- (5) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- (6) (2E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (34) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- (35) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (41) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,
- (42) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,
- (43) (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-2-propenamide,
- (44) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,
- (45) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,
- (46) (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-(2-phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenamide,
- (54) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- (55) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,

(56) (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-2-propenamide,

(57) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,

(58) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,

(59) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,

(60) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-N-(4-methylbenzenesulfonyl)-2-propenamide,

(61) (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-2-propenamide,

(62) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide, or

(63) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,

or a salt thereof.

Claim 17 (Previously Presented): The imidazole compound of claim 15, which is:

(E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propanamide,

(E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,

(E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide or

Application No. 09/869,135
Reply to Office Action of August 1, 2005

(E)-3-(4-chloro-1-(2-chloro-4-(phenylethyynyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,
or a salt thereof.

BASIS FOR THE AMENDMENT

Claims 7-8, 10, and 15-17 are active in the present application. Claims 1-6, 9 and 11-14 are canceled claims. Claim 8 has been amended to delete the term “prophylaxis”. Claim 10 has been amended to delete the term “preventing” from the preamble of the claim. Claims 8 and 10 have been amended to include atherosclerosis. Support for the amendment is found in the previously presented claims. Claim 16 has been amended for matters of form. No new matter is added.